Welcome to our dedicated page for Verve Therapeutics news (Ticker: VERV), a resource for investors and traders seeking the latest updates and insights on Verve Therapeutics stock.
This page provides a historical news archive for Verve Therapeutics, Inc. (former Nasdaq: VERV), a clinical-stage company that has focused on developing genetic medicines for cardiovascular disease. News coverage about Verve highlights its work on in vivo base editing and single-course gene editing medicines intended to permanently turn off genes in the liver that drive atherosclerotic cardiovascular disease and high-risk lipid disorders.
Articles in this feed describe Verve’s lead programs – VERVE-102, VERVE-201, and VERVE-301 – which target PCSK9, ANGPTL3, and LPA, respectively. News items detail clinical trial progress for VERVE-102 in the Heart-2 Phase 1b study in adults with heterozygous familial hypercholesterolemia and premature coronary artery disease, including reported dose-dependent reductions in LDL-C and PCSK9 protein levels and safety observations from early cohorts. Other updates cover the Pulse-1 Phase 1b trial of VERVE-201 in refractory hypercholesterolemia and homozygous familial hypercholesterolemia, as well as preclinical and collaboration milestones for VERVE-301 aimed at lowering lipoprotein(a).
In addition to clinical and regulatory updates, the news stream includes announcements about U.S. FDA Fast Track designation for VERVE-102, investigational new drug clearance, equity inducement grants, investor conference participation, and quarterly pipeline summaries. A significant portion of the coverage also relates to Eli Lilly and Company’s agreement to acquire Verve, the tender offer for Verve’s common stock, and the completion of the merger that resulted in Verve becoming an indirect wholly-owned subsidiary of Eli Lilly.
Because Verve’s common stock has been delisted from Nasdaq and the company has suspended its SEC reporting obligations, this page functions as a historical record of VERV-related news, useful for investors and researchers analyzing the development of single-course gene editing approaches in cardiovascular disease and the corporate events leading to Verve’s acquisition.
Verve Therapeutics, a clinical-stage biotechnology firm, will have its CEO, Sekar Kathiresan, present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 4:30 p.m. PT in San Francisco. The live presentation will be accessible via webcast, archived for 30 days. Verve focuses on innovative gene editing therapies for cardiovascular disease, notably through programs VERVE-101 and VERVE-201, aimed at lowering LDL cholesterol levels to combat heart disease.
Verve Therapeutics, a clinical-stage biotechnology firm, focuses on innovative gene editing therapies for cardiovascular diseases. CEO Sekar Kathiresan will present at two investor conferences: the Jefferies London Healthcare Conference on November 15, 2022, and the Evercore ISI Virtual HealthCONx Conference on November 29, 2022. These events will be broadcast live and archived for 60 days. Notably, their programs VERVE-101 and VERVE-201 aim to lower LDL cholesterol levels by targeting specific genes, potentially transforming chronic care into a single treatment solution.
Verve Therapeutics announced that the FDA has placed a hold on its IND application for VERVE-101, an investigational gene editing treatment for heterozygous familial hypercholesterolemia (HeFH). Despite this, dosing has been completed in the first cohort of the heart-1 clinical trial in New Zealand and the U.K., with no adverse events reported. The company is well-capitalized with $550.7 million in cash, enough to fund operations into the second half of 2025. R&D expenses rose to $35.2 million, contributing to a net loss of $45.2 million for Q3 2022.
Verve Therapeutics recently received the Paul Dudley White International Scholar Award from the American Heart Association for the highest-ranked abstract from the U.S. at Scientific Sessions 2022. This recognition is based on preclinical results for VERVE-101, a gene editing medicine targeting PCSK9 to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia (HeFH). The study in non-human primates showed significant reductions in both PCSK9 protein and LDL cholesterol levels, with no germline transmission. The data will be presented at the AHA meeting from November 5-7, 2022.
Verve Therapeutics, a biotechnology company focused on cardiovascular disease, has announced its participation in several investor conferences. Key events include the Guggenheim 2022 Nantucket Therapeutics Conference on September 28, the Jefferies Cell and Genetic Medicine Summit on September 29, the Chardan 6th Annual Genetic Medicine Conference on October 4, the BMO Virtual Biopharma Spotlight Series on October 6, and the Truist Securities Genetic Medicine Summit on October 20.
Live webcasts will be available on the company’s investor website for 60 days post-event.
Verve Therapeutics has received clearance for its Clinical Trial Authorization (CTA) application from the UK Medicines and Healthcare products Regulatory Agency for VERVE-101, aimed at treating heterozygous familial hypercholesterolemia (HeFH). This achievement marks the second regulatory clearance for VERVE-101, which is currently in the heart-1 clinical trial in New Zealand and set to begin patient enrollment in the UK. The trial aims to assess the safety and tolerability of VERVE-101 and gather interim clinical data in 2023, showcasing Verve's commitment to innovating cardiovascular disease care.
Verve Therapeutics has announced new preclinical data for its gene editing candidate, VERVE-201, aimed at treating homozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease. This candidate targets the ANGPTL3 gene in the liver, significantly impacting cholesterol metabolism. Promising results showed potent, on-target editing in human liver cells and substantial reductions in ANGPTL3 protein levels in non-human primates. The company plans to present this data at the European Society of Cardiology 2022 Congress on August 29, 2022, and anticipates moving towards clinical trials in 2024.
Verve Therapeutics reported significant advancements, including over $300 million added to its balance sheet, supporting operations well into the second half of 2025.
VERVE-101, aimed at treating heterozygous familial hypercholesterolemia, initiated patient dosing with interim clinical data expected in 2023. Regulatory clearances in the UK and US are anticipated soon.
The company also nominated VERVE-201 for ANGPTL3 treatment, with upcoming data presentations and IND-enabling studies in the pipeline. Additionally, new board members were appointed to bolster strategic growth.
Verve Therapeutics (Nasdaq: VERV) has successfully closed an upsized public offering of 9,583,334 shares at $27.00 per share, generating gross proceeds of $258.8 million. The offering's total includes 1,250,000 shares from underwriters' exercised options. Shares were sold under a shelf registration statement approved by the SEC. This financing aims to advance Verve's gene editing therapies targeting cardiovascular disease.
Verve Therapeutics, Inc. (Nasdaq: VERV) announced an upsized underwritten public offering of 8,333,334 shares of its common stock priced at $27.00 each, aiming for approximately $225 million in gross proceeds. The offering, fully underwritten, is set to close on July 25, 2022, subject to customary conditions. Additionally, underwriters may purchase up to 1,250,000 additional shares. Verve plans to utilize the funds to advance its gene editing therapies targeting cardiovascular disease, particularly focusing on PCSK9 and ANGPTL3.